Compare GETY & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GETY | GHRS |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.0M | 892.0M |
| IPO Year | N/A | 2021 |
| Metric | GETY | GHRS |
|---|---|---|
| Price | $1.45 | $14.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $4.76 | ★ $30.11 |
| AVG Volume (30 Days) | ★ 1.8M | 381.0K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $946,327,000.00 | N/A |
| Revenue This Year | $2.51 | N/A |
| Revenue Next Year | $2.90 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.10 | N/A |
| 52 Week Low | $1.25 | $6.72 |
| 52 Week High | $3.87 | $20.50 |
| Indicator | GETY | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 35.42 | 49.86 |
| Support Level | $1.44 | $13.71 |
| Resistance Level | $1.64 | $15.50 |
| Average True Range (ATR) | 0.09 | 0.90 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 19.64 | 40.31 |
Getty Images Holdings Inc. is a visual content creator and marketplace that offers a full range of content solutions. Through its Getty Images, Stock, and Unsplash brands, websites, and APIs, it serves customers around the world by allowing them to discover, purchase, and share visual content from photographers, illustrators, image partners, and videographers. The company generates a majority of its revenue through subscriptions, offering various subscription products on the Getty Images, iStock, and Unsplash websites. It operates and manages one operating segment, which is the business of developing and commercializing visual content. Geographically, the company generates maximum revenue from the Americas, followed by Europe, the Middle East and Africa, and the Asia-Pacific region.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.